Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors

Table 4 The association between hyperthyroidism and breast cancer polygenic risk scores (PRS) among women in the KARMA cohort (N = 11,991)

	No.	No. case	OR1 (95% CI)	OR2 (95% CI)
PRS for BC overall
Q1	2952	46	1.00 (REF)	1.00 (REF)
Q2	2952	46	1.05 (0.69–1.59)	1.08 (0.71–1.64)
Q3	2964	34	0.93 (0.55–1.56)	0.95 (0.56–1.60)
Q4	2937	60	1.90 (1.05–3.45)	1.98 (1.09–3.60)
P for trend			0.07	0.06
Standardized continuous			1.19 (0.96–1.48)	1.21 (0.97–1.50)
PRS for ER + BC
Q1	2953	44	1.00 (REF)	1.00 (REF)
Q2	2948	50	1.19 (0.79–1.80)	1.22 (0.81–1.85)
Q3	2965	33	0.91 (0.54–1.53)	0.93 (0.55–1.57)
Q4	2939	59	1.83 (1.01–3.30)	1.90 (1.04–3.43)
P for trend			0.09	0.07
Standardized continuous			1.18 (0.96–1.46)	1.20 (0.97–1.48)
PRS for ER − BC
Q1	2952	45	1.00 (REF)	1.00 (REF)
Q2	2958	41	0.92 (0.60–1.41)	0.93 (0.61–1.43)
Q3	2947	51	1.16 (0.77–1.75)	1.19 (0.79–1.80)
Q4	2948	49	1.12 (0.73–1.72)	1.15 (0.75–1.77)
P for trend			0.41	0.33
Standardized continuous			1.07 (0.92–1.25)	1.09 (0.93–1.27)

Analysis was performed among KARMA women without breast cancer and who had genotyped data. OR1s were adjusted for age, array of genotyping, and principle components. OR2s were additionally adjusted for BMI, menopausal status, age at menarche, number of births, family history of breast cancer, HRT use, oral contraceptive use, and benign breast disease. Statistically significant results are bolded
No. case the number of hyperthyroidism patients, No. the number of women without hyperthyroidism, OR odds ratio, CI confidence interval, ER estrogen receptor

ISSN: 1741-7015